Skip to content

Advertisement

  • Research article
  • Open Access

MBL2 gene polymorphism rs1800450 and rheumatic fever with and without rheumatic heart disease: an Egyptian pilot study

  • 1Email author,
  • 1,
  • 2,
  • 2 and
  • 1
Pediatric Rheumatology201816:24

https://doi.org/10.1186/s12969-018-0245-x

Received: 2 January 2018

Accepted: 6 April 2018

Published: 13 April 2018

Abstract

Background

Rheumatic fever (RF) is the result of an autoimmune response to pharyngitis caused by infection with Streptococcus pyogenes. RF is most prevalent in Africa and the Middle East. Rheumatic heart disease (RHD) is the most serious complication of RF. Mannose-binding lectin 2 gene (MBL2) has been reported to be correlated with different cardiac conditions. In Egyptian patients as a new studied ethnic population, it is the first time to evaluate the association between MBL2 gene polymorphism rs1800450 and RF with and without RHD.

Methods

One hundred and sixty RF patients (80 with RHD and 80 without RHD) and eighty healthy ethnically matched controls were studied. MBL2 (rs1800450) was genotyped by real-time PCR using TaqMan® allele discrimination assay. The MBL level was measured by ELISA. Westergren erythrocytes sedimentation rate (ESR), anti-streptolysin O titer (ASOT), C-reactive protein (CRP) and complements (C3 and C4) were determined.

Results

The AA genotype with high production of MBL was associated with increased risk of RHD more than the B allele carrying subjects. However, MBL2 genotype related to the low production of MBL was more frequently observed in those patients without RHD.

Conclusions

Our results suggested the involvement of MBL2 (rs1800450) polymorphism and its protein in RHD pathogenesis. Also, it might be a promising future strategy to utilize this polymorphism to help differentiate patients with RHD from those without RHD.

Keywords

  • Rheumatic fever
  • Rheumatic heart disease
  • MBL2 gene polymorphism

Background

Globally, rheumatic heart disease (RHD) is still the leading cause of acquired heart disease among the young [1]. Many echocardiographic screening studies put the prevalence of RHD at 8–57 out of 1000 children meaning that the prevalence may rest closer to 62–78 million individuals worldwide with up to 1.4 million deaths each year [2, 3]. A large African study indicated that RHD prevails as the most frequent cause of heart failure (HF) among children and young adults [4].

Despite being preventable and imminently treatable disease, sadly, RHD can go undetected until patients’ presentation with debilitating HF. At this stage, surgery is the only possible treatment option [5]. Patients living in poor countries have limited or no access to expensive heart surgery. To prevent these serious complications, it is very important to find out the most patients vulnerable to RHD to receive their further medical follow-up.

The main hypothesis for RF development is an autoimmune reaction resulting from molecular mimicry between streptococcal antigen and cardiac, articular and central nervous system proteins [6].

The innate immune response provides the first line of defense against Streptococcus pyogenes infections, in the case of RF, with complement cascade activation. Mannose-binding lectin (MBL) is an acute phase inflammatory protein and functions as a soluble pathogen recognition receptor. It binds to a wide variety of sugars on the surface of pathogens and plays a major role in innate immunity due to its ability to opsonize pathogens, enhancing their phagocytosis and activating the complement cascade via the lectin pathway [7]. N-acetylglucosamine, one of the main constituents of the streptococci cell wall [8] and of human heart valves [9] is a strong ligand for MBL.

Upon binding of the MBL’s higher-order oligomers to the identified carbohydrates moieties, they form complexes with MBL-associated serine proteases (MASPs), which help in activation of the complement system through the lectin pathway and generation of multiple opsonic and inflammatory fragments, which ultimately result in phagocytosis and several immune-mediated reactions [7].

The MBL2 gene is located on the chromosome 10 and comprises four exons. Inherited MBL insufficiency, which results in impaired innate immune function and enhanced susceptibility to infection, is essentially caused by three structural variants in exon 1. These three polymorphisms alter significantly the serum concentrations of MBL, with the variant alleles (D, B, C) resulting from mutations in codons 52, 54 and 57, respectively. The variant alleles are collectively named O, and the normal allele, A. The allele D changes CGT to TGT, changing arginine to cysteine (p.Arg52Cys). The B allele changes GGC to GAC and causes an amino acid replacement of glycine to aspartic acid (p.Gly54Asp) while the allele C changes GGA to GAA substituting glycine to glutamic acid (p.Gly57Glu) [7, 10].

Single nucleotide polymorphism (SNP) B, as it designates an exchange of the glycine in the glycine-rich motif, is associated with a decreased stability of the collagenous region of the protein. Although this MBL2 variant is indeed able to form multimers [11], they are more rapidly degraded and exist primarily as lower order oligomers. Functionally, they have a lower binding capacity to N-acetylglucosamine and do not activate complement [12], presumably due to lacking the capability of binding to MASPs [13].

The information surrounding the role of MBL2 polymorphism in RF pathogenesis remains insufficient. Few previous studies on limited ethnic population showed a direct variation about the MBL2 genotypes associated with the risk of RF and RHD [10]. Based on these findings, the current study was the 1st to demonstrate the association between MBL2 gene polymorphism and RF in Egyptians of different ethnic groups than the most of the studies and as a part of North Africa and the Middle East. And to find if there is a clinical value for this SNP to be predictive for RF complications.

Methods

Patients and control

This study was conducted on 160 patients with a history of RF chosen from outpatient RF Clinic, Abol-Reich Hospital, Kasr Al-Aini School of Medicine; Cairo University at the period between January 2015 and June 2015. RF patients were divided into 80 patients with RHD and 80 patients without RHD. Our patients were cases diagnosed, 4 to 12 months before enrolled in the study and not acute RF. All included patients were on monthly intramuscular injection of long-acting penicillin (benzathine penicillin) since their first diagnosis. No one required valvular heart surgery as no one was in HF. The control group included eighty healthy subjects matched with the patients for the ethnic, geographic and socioeconomic background. The study was approved by ethical committee of Abol-Reich Hospital. A written informed consent was obtained from all study subjects or their parents. The diagnosis of RF was made using the modified Jones criteria [14]. Patients presenting infective endocarditis, congenital heart diseases or other inflammatory or immunological disorders were excluded from this study. All the patients were subjected to complete history taking, thorough clinical examination as well as revision of their pre-registered data which included their laboratory investigations. Echocardiography was performed in all patients to assess the valve affection and all patients with RHD had a history of mild to moderate mitral valve regurge. The diagnosis of RHD was based on World Heart Federation criteria [15]. Overnight fasting blood samples from control and all patients were obtained. Each blood sample was distributed into three tubes; the first tube contained citrate, used for determination of 1st-hour erythrocytes sedimentation rate (ESR) using Westergren method [16]. The second tube was allowed to clot for 30 min and then centrifuged at 4000 rpm for 10 min. The obtained sera were used for determination of anti-streptolysin O titer (ASOT), C-reactive protein (CRP), complements (C3 and C4) by turbidimetric immunoassay method using commercially available kits (BioSystems S.A., Costa Brava, Barcelona, Spain). Serum MBL concentration was measured by enzyme-linked immunosorbent assay (ELISA) using commercial kits (Boster Biological Technology Co., Ltd., Pleasanton, USA) according to manufacturer’s instructions and recommendations.

Genetic analysis

The third tube contained EDTA, used for genomic DNA (gDNA) extraction and purification using Gene JET™ Whole Blood DNA Purification Mini Kit (Thermo Fisher Scientific Inc., USA) and then stored at − 80 °C until analyzed. The gDNA concentration and purity (A260/280) for each sample was determined using NANODROP™ 2000 spectrophotometer (Thermo Fisher Scientific Inc., USA). The extracted DNA was genotyped for MBL2 (AB; codon 54, rs1800450) exon 1 polymorphism by StepOne™ (Applied Biosystems, CA, USA) real-time polymerase chain reaction (PCR) using TaqMan® allele discrimination assay (Applied Biosystems, CA, USA). Probes and primers were designed by Applied Biosystems (ID: C_2336609_20), context sequence TGGTTCCCCCTTTTCTCCCTTGGTG[C/T]CATCACGCCCATCTTTGCCTGGGAA. Further details are restricted to Applied Biosystems and cannot be provided. TaqMan PCR was performed in a total volume of 20 μl (20 ng of DNA, 10 μl TaqMan master mix and 0.5 μl TaqMan® allele discrimination assay) placed in 48-well plates. Thermal cycling conditions were initiated by AmpliTaq Gold® polymerase activation at 95 °C for 10 min, followed by 45 cycles (denaturation at 95 °C for 15 s, then annealing/extension at 60 °C for 1 min). After PCR amplification, an endpoint plate read was carried out using the Applied Biosystems real-time PCR system. The fluorescence measurements that made during the plate read used by the sequence detection system software to plot the fluorescence values based on the signals from each well. The plotted fluorescence signals indicated which alleles are in each sample.

Statistical analysis

GraphPad Prism 6.0 (GraphPad software 2010, San Diego, USA) was used for analysis. Data of the groups were analyzed by D’Agostino and Pearson omnibus normality test to determine the normal distribution pattern. Normally distributed variables are presented as mean ± SE. Skewed distributed variables are presented as median (inter-quartile range). All results were compared by Kruskal-Wallis test (with multiple comparisons using Dunn’s test). Correlations between variables were tested using the Spearman’s correlation coefficients. The genotypes distribution for polymorphism was analyzed for deviation from the Hardy–Weinberg equilibrium (HWE) and any deviation between the observed and expected frequencies was tested for significance using the χ2 test. Differences in genotype and allele frequencies between groups were analyzed using the Fisher’s exact tests. In addition, we calculated the odds ratios (ORs) and 95% confidence intervals (CIs) regarding the presence RHD with respect to the existence of the polymorphism. All statistical tests were two-sided. A p-value < 0.05 was considered to be statistically significant. The receiver operator characteristic (ROC) curve was constructed to obtain the diagnostic accuracy, cutoff values, sensitivity and specificity for MBL. As an accuracy indicator, the area under the curve (AUC) was used for assessment of the diagnostic performance.

Results

Regarding ASOT, 1st-h ESR, CRP and C3, significantly increased values were obtained in RF patients without RHD as compared to control. Also, RF patients with RHD showed significantly increased values concerning to 1st-h ESR, CRP, C3 and MBL as compared to controls. In addition, MBL showed significantly increased values in RF patients with RHD as compared to both patients without RHD and controls. However, a significant decrease of CRP was obtained in RF patients with RHD as compared to those without RHD as shown in Table 1.
Table 1

Characteristics of the 240 study subjects

Characteristics

Controls

(n = 80)

RF (n = 160)

Without RHD (n = 80)

With RHD (n = 80)

Gender

Female n (%)

48 (60.0)

46 (57.5)

48 (60.0)

Male n (%)

32 (40.0)

34 (42.5)

32 (40.0)

Age (years)

15.2 ± 0.29

14.5 ± 0.43

14.3 ± 0.33

ASOT (IU/ml)

29.0 (11.3–97.0)

116 (26.3–172) a

63.0 (19.0–127)

1st-h ESR (mm/h)

6.00 (5.00–8.00)

21.5 (13.25–31.50) a

16.5 (11.00–25.0) a

CRP (mg/l)

2.90 (1.70–3.87)

6.55 (5.75–7.37) a

4.30 (3.10–6.25) a, b

C3 (mg/dl)

108.0 (98.0–122)

122.5 (111–136) a

127.5 (113–139) a

C4 (mg/dl)

30.5 (21.0–36.8)

31.5 (27.3–37.8)

32.0 (26.0–36.0)

MBL (ng/ml)

450.6 (290.2–563.1)

591.2 (478.0–1005)

1614 (1419–1945) a, b

Data are presented as n (%), mean ± SE or median (inter-quartile range)

a significant from control group, b significant from RF without RHD group

Using ROC curve analysis, we found that the critical serum level of MBL associated with the risk of RHD was 1383 ng/ml (AUC = 0.74, SE = 0.037, 95% CI = 0.67 to 0.82, p = < 0.0001, 73.3% sensitivity and 80% specificity).

The RF patients showed negative significant correlations between (MBL) against ASOT (r − 0.22, p 0.013), 1st-hr ESR (r − 0.2, p 0.026), and CRP (r − 0.25, p 0.005). However, MBL showed negative insignificant correlations with C3 (r − 0.03, p 0.757) and C4 (r 0.016, p 0.86).

The genotype distribution for the studied SNP (AB; codon 54, rs1800450) showed no deviation from HWE. Higher frequency of the AA genotype was present in patients with RHD when compared to controls. However, a lower frequency of AB and BB genotypes was observed in RHD patients as compared to healthy controls. In addition, a lower frequency of the B allele was observed in RF patients with RHD when compared to the controls. Patients without RHD showed insignificant differences in the frequency of all genotypes and B allele when compared to controls, as illustrated in Tables 2 and 3.
Table 2

Distribution of MBL2 genotypes (rs1800450) in patients with history of RF and controls

 

Controls

(n = 80)

RF (n = 160)

p

OR

95% CI

 

Without RHD

(n = 80)

With RHD

(n = 80)

Genotypes

      

AA n (%)

44 (55)

42 (52.5)

69 (86.25)

1.00 a

0.90

0.37–2.17

0.0003 b

5.13*

2.10–12.5

AB n (%)

24 (30)

34 (42.5)

11 (13.75)

0.50 a

1.48

0.57–3.84

0.02 b

0.29*

0.11–75.0

BB n (%)

12 (15)

4 (5)

0 (0)

0.26 a

0.29

0.06–1.58

0.001 b

0.03*

0.002–0.60

HWE

χ2 = 3.3, p > 0.05

χ2 = 0.38, p > 0.05

χ2 = 0.44, p > 0.05

   

OR of AA: by comparison between AA versus (AB+BB) (dominant model)

OR of AB: by comparison between AB versus AA (co-dominant model)

OR of BB: by comparison between BB versus (AA+AB) (recessive model)

a RF without RHD versus controls. b RF with RHD versus controls

* significant difference at p < 0.05

Table 3

Distribution of MBL2 alleles (rs1800450) in patients with history of RF and controls

 

Controls (n = 80)

RF (n = 160)

p

OR

95% CI

 

Without RHD (n = 80)

With RHD (n = 80)

Allele

      

A n (%)

112 (70)

118 (73.8)

149 (93.1)

   

B n (%)

48 (30)

42 (26.2)

11 (6.9)

0.720 a

0.83

0.42–1.65

0.0001b

0.17*

0.08–0.37

a RF without RHD versus controls. b RF with RHD versus controls

* significant difference at p < 0.05

In this study, RF group was classified according to the MBL2 gene (rs1800450) genotypes into subjects carrying AA genotype and subjects carrying AB+BB genotypes. As shown in Table 4, regarding C4, a significant difference was found between AA of RF group as compared to AB+BB. Looking at the MBL level, the genotype AA in RF group was associated with highly significant concentrations of MBL in serum as compared to individuals carrying the B allele (AB+BB) in the same group. In genotype AB+BB individuals, the MBL levels were reduced 4 times than AA genotype.
Table 4

Biochemical and demographic characteristics of RF patients according to MBL2 gene (rs1800450) genotypes

  

RF patients

  

AA

AB+BB

Age (years)

14.44 ± 0.30

14.35 ± 0.55

ASOT (IU/ml)

64.5 (19–139.5)

113 (28–189)

1st-h ESR (mm/h)

17 (11–25)

23.5 (14–42.25)

CRP (mg/l)

5.1 (3.5–6.8)

6.2 (5.1–7.9)

C3 (mg/dl)

122.5 (112.8–135.0)

134 (110.8–146)

C4 (mg/dl)

32 (26–36)

25 (19.75–30.25) a

MBL (ng/ml)

1544 (1328–1906)

412.9 (338–501.2) a

Data are presented in mean ± SE or median (inter-quartile range)

a significant difference between AB+BB and AA at p < 0.05

Discussion

Despite the vital role of the lectin pathway in complement activation and host defense against infection and autoimmunity, studies on the significance of components of this pathway in RF and RHD are still scarce [17, 18].

In the current study, regarding ASOT, significantly increased values were found in RF group without RHD as compared to control, which was confirmed by Sainani and Sainani, [19] who reported that the significant increase of ASOT in RF group as compared to control may be explained by recent streptococcal infection in RF patients.

In agreement with Kumar [20] and Farghaly et al., [21], concerning the 1st-h ESR and CRP, there were significantly increased values in RF group as compared to control. These elevations may be explained by the ongoing inflammatory nature of the disease as suggested by Gölbasi et al., [22], Veasy and Tani, [23] and Chiu-Braga et al., [24].

Given the level of C3, it was significantly increased in RF group than the control subjects which is in agreement with Schafranski et al., [25, 26] who suggested the presence of continuous inflammation with probable complement activation. The C3 is an acute phase protein which significantly increases in response to infections or to an inflammatory reaction.

However, the involvement of complement system in RF and RHD has been shown in different studies. Antibodies found in RF patients’ sera that show molecular mimicry between streptococcal and human antigens were able to cause human fibroblasts lyses in vitro in the presence of complement [25].

These results confirmed the involvement of complement system components in the pathogenesis of RF as described by Schafranski et al., [26].

As the best to our knowledge, this is the 1st study in Egypt evaluating MBL levels and MBL2 genotype (A/B; codon 54, rs1800450) in the development of RF.

In the current study, the level of MBL was significantly higher in patients with RHD than both controls and patients without RHD, indicating the high MBL levels could be a cause of undesirable complement activation in carditis patients, contributing to the pathogenesis of rheumatic cardiomyopathy [25]. This result may encourage further studies on anti-MBL as an interesting alternative therapy for patients with this disease.

The negative significant correlation between serum MBL and ASOT in this study could be explained by the subsequent triggering of MBL to the complement system that may be responsible for either a direct complement-dependent killing of the bacteria or increased phagocytosis through the opsonization [27]. These findings confirmed the positive impact of MBL in streptococcal innate immune defense.

The current study showed a significant negative correlation between MBL and ESR that may be explained by either the expression of functional MBL protein is largely genetically determined by polymorphisms found in the first exon of the structural gene [28] or by the characteristic pattern of ESR in rheumatic disease [29].

Our results disclosed a negative significant correlation between MBL and CRP levels that may be related to the following two different functional mechanisms: 1) MBL is involved in the lectin pathway while CRP is involved in the classical complement activation pathway. 2) Although, both MBL and CRP have a common terminal pathway, MBL mainly plays a role in the early responses of the host innate immune system, while CRP mainly plays a role in the late stage of adaptive immune responses [30].

However, in the current study, there were insignificant correlations between C3, C4 and MBL levels, indicating that elevated MBL concentration might be an independent event [31].

In the present study, the homozygous wild genotype AA was more prevalent in patients with RHD than healthy controls. In addition, the frequency of variant allele B was significantly lower in patients with RHD than controls. These findings were in accordance with Schafranski et al., [26] and Reason et al., [32], who concluded that the AA genotype could be involved in the development of cardiac manifestation in RF and the relationship was due to genetic effect of MBL2 polymorphisms rather than to an acute phase reaction. They also suggested a role for AA MBL2 genotype in the susceptibility to rheumatic carditis.

Many previous studies reported the association between MBL deficiency and risk of recurrent different infections [33]. While RF is a result of untreated streptococcal pharyngeal infection [6], previous studies [26, 32] and our results suggested an association between high MBL levels and RF that could be explained by the auto immune nature of RF and RHD [34]. Moreover, the role of MBL in the pathogenesis of rheumatic carditis could be related to the stressful conditions and the inflammatory processes of this carditis which could result in glycosylation of the self-cell surfaces [35]. In the heart valves of RF patients, there is a lot of myxomatous tissue which rich in hyaluronic acid. The N-acetylglucosamine is a major constituent of this hyaluronic acid. So, it can act as a ligand for the high levels of MBL that argue the chronic inflammatory activity present in the RHD individuals and contribute to valve injury through complement activation [9]. In addition, MBL may act as an immunomodulatory molecule, inducing a higher secretion of cytokines by macrophages [36].

Thus, the high blood concentrations of MBL could be considered as a double-edged sword molecule in the physiopathology of RF and rheumatic carditis, on one hand conferring protection against the initial infection by rheumatogenic Streptococci which is good, but on the other hand eliciting inflammation and complement dependent tissue damage in the chronic stage of the disease [10].

In contrast to the previous results, in an initial study in Chinese patients, there was no association between the B allele and RHD [37]. However, they suggested an assumed role for MBL deficiency in the progression of RHD, by considering their patient’s age of onset of heart disease. The mean age of onset of cardiac symptoms of patients with the deficient B allele was significantly lower compared with patients with MBL2 genotype AA. These findings supported the hypothesis that MBL deficiency caused by the B allele could facilitate the development and accelerate the progression of RHD in younger people. In addition, higher levels of serum MBL in control group as compared to RHD patients were reported by Scalzi et al. [38] in Yemen population.

Also, in another study on patients from São Paulo, Brazil who suffered from chronic severe rheumatic aortic regurgitation (AR), Ramasawmy et al., [39] observed that B allele had similar frequencies in both AR patients and controls. They postulated that continuous exposure to Streptococcus antigens in MBL-deficient individuals would lead to the subsequent abnormal immune response against heart proteins, leading to rheumatic AR. Studies done on MBL2 gene polymorphisms in RHD could be summarized in Table 5.
Table 5

Studies on MBL2 gene polymorphism in RHD

Polymorphism

Population

Polymorphism association

Refs

− 221 XY

A (52C, 54G, 57G),

O (52T, 54A, 57A)

Brazilian

RHD patients with mitral valve lesion showed an association with the A allele

[26, 32]

A (52C, 54G, 57G),

O (52T, 54A, 57A)

Chinese

RHD displayed no association with the B allele

[37]

A (52C, 54G, 57G),

O (52T, 54A, 57A)

Brazilian

RHD patients with AR displayed an association with the O allele

[39]

The contradiction between these results could be attributed to the difference in ethnicity, clinical manifestations of the studied subjects or due to the difference in the sample size.

In the present study, it was found that the AA genotype of RF patients was associated with high levels of MBL as compared to subjects carrying AB+BB in the same group indicating the suppressive effect of the mutant B allele on the levels of serum MBL that was in agreement with Reason et al., [32] and Schafranski et al., [26].

Some limitations should be considered when interpreting this study results. First, the sample size of the selected patients is not large enough to give a bigger picture about the distribution of MBL2 genotypes. So, further larger sample studies are recommended to verify these findings in Egyptians and other Mediterranean ethnics. Second, the selected SNP was based on the scientific literature, other SNPs may be more prominently implicated in our study included ethnics. Third, this study was independent on patients’ follow-up while the long-term follow-up of patients with RF without valve consequence is necessary in order to identify which patients actually progress to RHD and the risk factors associated with it. Fourth, the age of our studied population may not allow a homogeneous representation of the population with RF.

Conclusions

The AA genotype associated with a higher production of MBL seems to represent a risk factor for the development of RHD. In addition, the highly significant frequencies of B allele in both controls and patients without RHD when compared to patients with RHD may indicate that the presence of B allele would be a protective factor against rheumatic carditis. In addition, this polymorphism could be suggested in the differentiation between RF patients with and without RHD.

Abbreviations

AR: 

Aortic regurgitation

ASOT: 

anti-streptolysine O titer

C3: 

complement 3

C4: 

complement 4

CRP: 

C-reactive protein

ESR: 

erythrocyte sedimentation rate

HF: 

heart failure

MASPs: 

MBL-associated serine proteases

MBL: 

mannose-binding lectin

RF: 

rheumatic fever

RHD: 

rheumatic heart disease

SNP: 

Single nucleotide polymorphism

Declarations

Acknowledgements

We gratefully acknowledge the cooperation of the patients and their families and normal control individuals involved in this study.

Authors’ contributions

MHG acquired the data. MHG and MMB carried out the molecular genetic studies. MHG did the literature search and the statistical analysis, and wrote the paper. SSA and HSH participated in study design and coordination and helped to draft the manuscript. MHG and AMF interpreted the data and were responsible for the manuscript preparation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by ethical committee of Abol-Reich Hospital. A written informed consent was obtained from all study subjects or their parents.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Biochemistry Department-Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt
(2)
Department of Pediatrics, Kasr Al-Aini School of Medicine, Cairo University, Cairo, Egypt

References

  1. Zuhlke L, Mirabel M, Marijon E. Congenital heart disease and rheumatic heart disease in Africa: recent advances and current priorities. Heart. 2013;99(21):1554–61.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Zuhlke L, Mayosi BM. Echocardiographic screening for subclinical rheumatic heart disease remains a research tool pending studies of impact on prognosis. Curr Cardiol Rep. 2013;15(3):343.View ArticlePubMedGoogle Scholar
  3. Zuhlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, Mauff K, Islam S, Joachim A, Daniels R, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the global rheumatic heart disease registry (the REMEDY study). Eur Heart J. 2015;36(18):1115–1122a.View ArticlePubMedGoogle Scholar
  4. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the sub-Saharan Africa survey of heart failure. Arch Intern Med. 2012;172(18):1386–94.View ArticlePubMedGoogle Scholar
  5. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Circulation. 2014;129(23):2440–92.View ArticlePubMedGoogle Scholar
  6. Carapetis JR, Beaton A, Cunningham MW, Guilherme L, Karthikeyan G, Mayosi BM, Sable C, Steer A, Wilson N, Wyber R: PRIMER. 2016.Google Scholar
  7. Takahashi K, Ip WE, Michelow IC, Ezekowitz RA. The mannose-binding lectin: a prototypic pattern recognition molecule. Curr Opin Immunol. 2006;18(1):16–23.View ArticlePubMedGoogle Scholar
  8. Guilherme L, Ramasawmy R, Kalil J. Rheumatic fever and rheumatic heart disease: genetics and pathogenesis. Scand J Immunol. 2007;66(2–3):199–207.View ArticlePubMedGoogle Scholar
  9. Nayar S, Nayar PG, Cherian KM. Heart valve structure: a predisposing factor for rheumatic heart disease. Heart. 2006;92(8):1151–2.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Beltrame MH, Catarino SJ, Goeldner I, Boldt AB, de Messias-Reason IJ. The lectin pathway of complement and rheumatic heart disease. Front Pediatr. 2014;2(148):148.PubMedGoogle Scholar
  11. Super M, Gillies SD, Foley S, Sastry K, Schweinle JE, Silverman VJ, Ezekowitz RA. Distinct and overlapping functions of allelic forms of human mannose binding protein. Nat Genet. 1992;2(1):50–5.View ArticlePubMedGoogle Scholar
  12. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency--revisited. Mol Immunol. 2003;40(2–4):73–84.View ArticlePubMedGoogle Scholar
  13. Matsushita M, Ezekowitz RA, Fujita T. The Gly-54-->Asp allelic form of human mannose-binding protein (MBP) fails to bind MBP-associated serine protease. Biochem J. 1995;311 (Pt 3)(3):1021–3.View ArticleGoogle Scholar
  14. Gewitz MH, Baltimore RS, Tani LY, Sable CA, Shulman ST, Carapetis J, Remenyi B, Taubert KA, Bolger AF, Beerman L, et al. Revision of the Jones criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131(20):1806–18.View ArticlePubMedGoogle Scholar
  15. Remenyi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, Lawrenson J, Maguire G, Marijon E, Mirabel M, et al. World heart federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline. Nat Rev Cardiol. 2012;9(5):297–309.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Gilmour D, Sykes AJ. Westergren and Wintrobe methods of estimating ESR compared. Br Med J. 1951;2(4746):1496–7.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Neth O, Jack DL, Dodds AW, Holzel H, Klein NJ, Turner MW. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun. 2000;68(2):688–93.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Boldt AB, Goeldner I, de Messias-Reason IJ. Relevance of the lectin pathway of complement in rheumatic diseases. Adv Clin Chem. 2012;56:105–53.View ArticlePubMedGoogle Scholar
  19. Sainani G, Sainani AR. Rheumatic fever-how relevant in India today? J Assoc Physicians India. 2006;54(N):42–7.PubMedGoogle Scholar
  20. Kumar R. Spectrum of clinical presentation of rheumatic fever and rheumatic heart disease patients. Annals of International Medical and Dental Research. 2016;2(3):49–51.Google Scholar
  21. Farghaly HS, Gad EF, Hassan A-EA, MAA A. Evaluation of Adrenomedullin levels in children with acute rheumatic Feverand its correlation to left ventricular function. American Journal of Medicine and Medical Sciences. 2017;7(2):74–8.Google Scholar
  22. Gölbasi Z, Uçar Ö, Keles T, Sahin A, Çagli K, Çamsari A, Diker E, Aydogdu S. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail. 2002;4(5):593–5.View ArticlePubMedGoogle Scholar
  23. Veasy LG, Tani LY. A new look at acute rheumatic mitral regurgitation. Cardiol Young. 2005;15(6):568–77.View ArticlePubMedGoogle Scholar
  24. Chiu-Braga Y, Hayashi S, Schafranski M, Messias-Reason I. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol. 2006;109(2):275–6.View ArticlePubMedGoogle Scholar
  25. Schafranski M, Stier A, Nisihara R, MESSIAS-REASON I. Significantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: a beneficial role for MBL deficiency. Clin Exp Immunol. 2004;138(3):521–5.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Schafranski MD, Pereira Ferrari L, Scherner D, Torres R, Jensenius JC, de Messias-Reason IJ. High-producing MBL2 genotypes increase the risk of acute and chronic carditis in patients with history of rheumatic fever. Mol Immunol. 2008;45(14):3827–31.View ArticlePubMedGoogle Scholar
  27. Yaroslavskyy O. The association of mannose-binding lectin with parameters of metabolic syndrome and early atherosclerosis markers. PhD, Universitat Regensburg. 2013;Google Scholar
  28. Eddie Ip W, Takahashi K, Alan Ezekowitz R, Stuart LM. Mannose-binding lectin and innate immunity. Immunol Rev. 2009;230(1):9–21.View ArticleGoogle Scholar
  29. Neto R, Salles N, JFd C. The use of inflammatory laboratory tests in rheumatology. Rev Bras Reumatol. 2009;49(4):413–30.View ArticleGoogle Scholar
  30. Liu XH, Li Q, Zhang P, Su Y, Zhang XR, Sun Q. Serum mannose-binding lectin and C-reactive protein are potential biomarkers for patients with community-acquired pneumonia. Genet Test Mol Biomarkers. 2014;18(9):630–5.View ArticlePubMedGoogle Scholar
  31. Lappegård KT, Garred P, Jonasson L, Espevik T, Aukrust P, Yndestad A, Mollnes TE, Hovland A. A vital role for complement in heart disease. Mol Immunol. 2014;61(2):126–34.View ArticlePubMedGoogle Scholar
  32. Reason IJM, Schafranski MD, Jensenius JC, Steffensen R. The association between mannose-binding lectin gene polymorphism and rheumatic heart disease. Hum Immunol. 2006;67(12):991–8.View ArticleGoogle Scholar
  33. Heitzeneder S, Seidel M, Förster-Waldl E, Heitger A. Mannan-binding lectin deficiency—good news, bad news, doesn't matter? Clin Immunol. 2012;143(1):22–38.View ArticlePubMedGoogle Scholar
  34. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol. 2010;30(1):17–23.View ArticlePubMedGoogle Scholar
  35. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 2000;156(5):1549–56.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol. 2003;40(7):423–9.View ArticlePubMedGoogle Scholar
  37. Jin Z, Ji Z, Hu J. Mannose-binding lectin gene site mutations and the susceptibility of rheumatic heart disease. Zhonghua Yi Xue Za Zhi. 2001;81(21):1284–6.PubMedGoogle Scholar
  38. Scalzi V, Hadi HA, Alessandri C, Croia C, Conti V, Agati L, Angelici A, Riccieri V, Meschini C, Al-Motarreb A, et al. Anti-endothelial cell antibodies in rheumatic heart disease. Clin Exp Immunol. 2010;161(3):570–5.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Ramasawmy R, Spina GS, Fae KC, Pereira AC, Nisihara R, Reason IJM, Grinberg M, Tarasoutchi F, Kalil J, Guilherme L. Association of mannose-binding lectin gene polymorphism but not of mannose-binding serine protease 2 with chronic severe aortic regurgitation of rheumatic etiology. Clinic Vaccine Immunol. 2008;15(6):932–6.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement